Combination treatment for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 85 years old.
- You have prostate cancer that has spread to your bones and is no longer controlled by hormone therapy or chemotherapy.
- You have had at least one prior treatment like abiraterone, enzalutamide, or docetaxel.
- You are willing to have a biopsy (tissue sample) taken before and during the study.
- You have not been treated with immunotherapy (like PD-1/PD-L1 inhibitors) before.
- You do not have cancer that has spread to organs like your liver or lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.